Abstract
Objective:
To evaluate the efficacy of troxerutin in chronic venous insufficiency.
Design:
Randomized, double-blind, multicentre, prospective controlled trial.
Setting:
Hôtel Dieu Hospital and Notre Dame de Bon Secours Hospital, Paris, France.
Patients:
Sixty-nine patients with truncal varicose veins.
Intervention:
After a single-blind 15-day placebo run-in period, one group (n = 34) received troxerutin 3500 mg daily for 2 months. The other group (n = 35) received a placebo.
Main outcome measures:
Subjective symptoms, ankle circumference, venous refilling time with photoplethysmography, erythrocyte aggregation using the SEFAM aggregameter and fibrinogen level.
Results:
Leg aching (p < 0.001) and venous function score (p < 0.001) improvements were significantly higher in the troxerutin group (83% and −3.7) compared with the placebo group (23% and −0.7). A significant difference in favour of troxerutin was found for erythrocyte aggregation kinetic indexes (p < 0.001) and dissociation threshold (p < 0.01).
Conclusions:
This study confirmed the dual action of the drug: a parietal effect and a rheological effect.
Get full access to this article
View all access options for this article.